These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 35840110)
1. Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial. Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):856-861. PubMed ID: 35840110 [TBL] [Abstract][Full Text] [Related]
2. Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial. Baker S; Jiang W; Mou B; Lund CR; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Chng N; Matthews Q; Arbour G; Benny A; Tyldesley S; Olson RA Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):617-626. PubMed ID: 35667528 [TBL] [Abstract][Full Text] [Related]
3. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial. Baker S; Mou B; Jiang W; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Berrang T; Bang A; Chng N; Matthews Q; Tyldesley S; Olson RA Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):849-855. PubMed ID: 36302495 [TBL] [Abstract][Full Text] [Related]
4. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial. Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355 [TBL] [Abstract][Full Text] [Related]
5. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial. Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619 [TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman GS; Warner A; Senan S Lancet; 2019 May; 393(10185):2051-2058. PubMed ID: 30982687 [TBL] [Abstract][Full Text] [Related]
7. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737 [TBL] [Abstract][Full Text] [Related]
8. Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial. Baker S; Lechner L; Liu M; Chang JS; Cruz-Lim EM; Mou B; Jiang W; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Arbour G; Yu I; Tyldesley S; Olson RA Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1497-1506. PubMed ID: 38220069 [TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer. Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P Front Oncol; 2022; 12():863609. PubMed ID: 35494057 [TBL] [Abstract][Full Text] [Related]
10. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. Siva S; Bressel M; Mai T; Le H; Vinod S; de Silva H; Macdonald S; Skala M; Hardcastle N; Rezo A; Pryor D; Gill S; Higgs B; Wagenfuehr K; Montgomery R; Awad R; Chesson B; Eade T; Wong W; Sasso G; De Abreu Lourenco R; Kron T; Ball D; Neeson P; JAMA Oncol; 2021 Oct; 7(10):1476-1485. PubMed ID: 34455431 [TBL] [Abstract][Full Text] [Related]
11. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study. Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855 [TBL] [Abstract][Full Text] [Related]
12. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial. Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662 [TBL] [Abstract][Full Text] [Related]